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Abstract
Exposure of biological membranes to reactive oxygen species
creates a complex mixture of distinct oxidized phospholipid (OxPL)
species, which contribute to the development of chronic inflamma-
tory diseases and metabolic disorders. While the ability of OxPL to
modulate biological processes is increasingly recognized, the
nature of the biologically active OxPL species and the molecular
mechanisms underlying their signaling remain largely unknown.
We have employed a combination of mass spectrometry, synthetic
chemistry, and immunobiology approaches to characterize the
OxPL generated from the abundant phospholipid 1-palmitoyl-2-
arachidonoyl-sn-glycero-3-phosphocholine (PAPC) and investigated
their bioactivities and signaling pathways in vitro and in vivo. Our
study defines epoxycyclopentenones as potent anti-inflammatory
lipid mediators that mimic the signaling of endogenous,
pro-resolving prostanoids by activating the transcription factor
nuclear factor E2-related factor 2 (Nrf2). Using a library of OxPL
variants, we identified a synthetic OxPL derivative, which allevi-
ated endotoxin-induced lung injury and inhibited development of
pro-inflammatory T helper (Th) 1 cells. These findings provide a
molecular basis for the negative regulation of inflammation by
lipid peroxidation products and propose a novel class of highly
bioactive compounds for the treatment of inflammatory diseases.
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Introduction
It is now increasingly recognized that oxidized phospholipids
(OxPL) do not just represent mere by-products of lipid peroxidation
associated with inflammatory conditions or increased oxidative
stress, but instead actively modulate cellular signaling processes
and contribute to the initiation and amplification of inflammation
(Berliner & Watson, 2005; Bochkov et al, 2010; Lee et al, 2012).
Particularly the polyunsaturated fatty acid side chains of membrane
phospholipids are highly susceptible to modification by reactive
oxygen intermediates, which potentially yields an enormous array
of distinct lipid oxidation products with diverse biological effects
(Leitinger, 2003; Berliner & Watson, 2005; Bochkov et al, 2010; Lee
et al, 2012). In contrast to the site-specific enzymatic oxidation reac-
tions that convert arachidonic acid into a panel of endogenous
inflammatory eicosanoid mediators, such radical-mediated oxida-
tion is non-specific; hence, even the oxidation of a single phospho-
lipid precursor containing arachidonic acid results in a very
complex mixture of individual OxPL species (Bochkov et al, 2010).
The pathophysiological relevance of OxPL was initially discovered
in atherosclerosis (Witztum & Steinberg, 1991; Berliner & Watson,
2005), but is now clearly evident for other diseases with a promi-
nent inflammatory component, including acute and chronic micro-
bial infections, lung injury, and neurodegenerative disorders
(Bochkov et al, 2002; Cruz et al, 2008; Imai et al, 2008; Weismann
et al, 2012). The majority of reports suggests strong pro-inflammatory
effects of OxPL, which might be explained by the interaction of
OxPL with pattern recognition receptors of the innate immune
system, such as Toll-like receptors (Imai et al, 2008; Seimon et al,
2010; Stewart et al, 2010), scavenger receptors (Podrez et al, 2002;
Stewart et al, 2010), complement components (Weismann et al,
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2012), or natural antibodies (Palinski et al, 1996; Binder et al,
2003). Nevertheless, several conflicting observations indicate that
OxPL may also dampen inflammatory responses, and OxPL-
mediated inhibition of TLR activation (Bochkov et al, 2002) as well as
phagocytosis (Knapp et al, 2007) has been proposed as underlying
mechanism. The discrepancy between potential pro- and anti-
inflammatory bioactivities of OxPL is not yet resolved. One possible
reason for such contradicting findings may lie in the different experi-
mental conditions used by different groups to generate their respec-
tive OxPL preparations, which may lead to different compositions of
the resulting bulk OxPL mixtures and could therefore explain the
different pro- or anti-inflammatory activities. A solution to this prob-
lem would be the use of isolated, synthetic OxPL species to elucidate
their mechanism of action and pathophysiological relevance. While
the first bioactive OxPL species have been identified and associated
with defined biological effects (Watson et al, 1997, 1999; Podrez
et al, 2002; Seimon et al, 2010; Zhong et al, 2013), our knowledge
on the contribution of such lipid species to the in vivo regulation of
inflammation and on the responsible signaling pathways remains
very limited.
Here, we have investigated the spectrum of OxPL species that is
generated during oxidative modification of a single, defined
phospholipid precursor. We chose 1-palmitoyl-2-arachidonoyl-sn-
glycero-3-phosphocholine (PAPC) for these experiments because of its
abundance in biological membranes and because of the relevance of
its oxidation products for inflammatory diseases, including acute
lung injury, microbial infection, and atherosclerosis (Watson et al,
1997; Bochkov et al, 2002; Podrez et al, 2002; Cruz et al, 2008; Imai
et al, 2008). Our study characterizes an anti-inflammatory bioactiv-
ity of OxPL that can be attributed to a single type of OxPL. We find
that this potent anti-inflammatory bioactivity is mediated by the
prostanoid-like OxPL component epoxycyclopentenone, which acti-
vates the transcription factor nuclear factor E2-related factor 2 (Nrf2)
to inhibit pro-inflammatory cytokine and chemokine responses in
myeloid cells in vitro and in vivo. Using a library of epoxycyclopen-
tenone variants, we have defined structural determinants of this
bioactivity and developed an epoxycyclopentenone derivative with
an unprecedented anti-inflammatory bioactivity. These results not
only implicate OxPL/Nrf2 signaling in the negative regulation of
inflammation, but also suggest a novel class of lipid mediators as
therapeutic agents for the treatment of inflammatory diseases.
Results
Oxidized phospholipids are potent inhibitors of the
pro-inflammatory response of myeloid cells
To examine the effects of OxPL signaling on innate immune
responses, synthetic PAPC was either oxidized by metal-catalyzed
oxidation or autoxidized by exposure to ambient air, and the bioac-
tivity of the resulting oxidized PAPC (OxPAPC) mixtures was evalu-
ated in vitro. Exposure of bone marrow-derived dendritic cells
(BMDC) to OxPAPC strongly inhibited their subsequent ability to
produce the pro-inflammatory cytokines interleukin (IL)-6 and IL-12
in response to stimulation of the Toll-like receptor (TLR) 7 with
imiquimod (Fig 1A). This potent anti-inflammatory bioactivity of
OxPAPC could be directly attributed to the oxidative modification of
PAPC, since treatment with 1,2-di-palmitoyl-sn-glycero-3-phospho-
choline (DPPC), a phospholipid with no unsaturated acyl chains that
is therefore inert to oxidation, did not show such effect (Fig 1A).
OxPAPC-treated cells produced reduced levels of IL-6 and IL-12
messenger RNA upon TLR stimulation, indicating that OxPL signal-
ing regulated these cytokine responses at the transcriptional level
(Fig 1B). While copper-catalyzed PAPC oxidation appeared to be
the most rapid and potent method to generate anti-inflammatory
OxPL species, also iron-oxidized and autoxidized OxPAPC prepara-
tions comparably inhibited the inflammatory response of myeloid
cells (Fig 1C). We concluded from this result that modification of
PAPC by reactive oxygen species generates anti-inflammatory OxPL
irrespective of the method used, albeit with different efficacy and
kinetics. Weak anti-inflammatory bioactivity was already detectable
after 2 h of copper-catalyzed PAPC oxidation (Fig 1D). The bioactiv-
ity of the OxPAPC preparation progressively increased to reach its
▸Figure 1. Oxidized phospholipids are potent inhibitors of the pro-inflammatory response of myeloid cells.A, B BMDCs were treated with OxPAPC or DPPC (40 lg/ml) for 60 min followed by R837 stimulation (5 lg/ml). (A) Supernatants were harvested after 18 h, and
concentrations of IL-6 and IL-12 were quantified by ELISA. One-way ANOVA adjusted by Dunnett’s multiple comparisons test. Mean  SD of triplicate
determinations from > 3 independent experiments are shown. (B) mRNA was harvested after 2 h, and expression of IL-6 and IL-12 was measured by real-time PCR
and normalized to G6pdx. Unpaired two-tailed t-test. Data (mean  SD) are representative of three independent experiments.
C Bioactive OxPAPC mixtures were obtained by various oxidation protocols from highly pure PAPC. Periods of oxidation were 24 h for CuSO4 (10 lM), 48 h for FeSO4
(10 lM), and 72 h for air. BMDCs were treated for 60 min with lipids prior stimulation with R837 (5 lg/ml) for 18 h. Cytokine concentrations in supernatants were
quantified by ELISA. One-way ANOVA adjusted by Dunnett’s multiple comparisons test. Data represent mean  SEM of triplicate determinations.
D PAPC (40 lg/ml) oxidized with CuSO4 (10 lM) for the indicated times was used for treatment of BMDCs prior to R837 (5 lg/ml) stimulation and measurement of
IL-12 secretion. Mean  SEM of triplicate determinations from three different oxidation series are shown.
E, F Treatment of BMDCs with the indicated concentrations of CuSO4-oxidized PAPC suppressed IL-6 (E) and IL-12 (F) secretion triggered by a variety of different TLR
agonists. After OxPAPC treatment for 60 min, BMDCs were stimulated for 18 h with LTA (500 ng/ml), Poly I:C (50 lg/ml), LPS (10 ng/ml), R837 (5 lg/ml), and CpG
(100 nM). Cytokine concentrations in the supernatant were quantified by ELISA. Data are shown as mean  SD of triplicate determinations from three
independent experiments and were analyzed by one-way ANOVA adjusted by Dunnett’s multiple comparisons test.
G–I Splenic dendritic cells were treated with OxPAPC or DPPC (40 lg/ml) before co-culturing with naïve transgenic SMARTA CD4 T cells in the presence of the specific
peptide gp61. (G) After 4 days of cell culture, T-cell polarization was assessed by intracellular staining for the cytokines IL-4 (Th2) and IFN-c (Th1). (H) Bar graphs
represent the frequencies of IL-4- and IFN-c-producing T cells after 4 days of co-culture with OxPAPC-treated and DPPC-treated splenic dendritic cells. Bars
represent mean  SD of duplicate experiments. *P ≤ 0.05 by unpaired two-tailed t-test. (I) IFN-c production in supernatants of SMARTA CD4 T cells (stimulated
with 1,000 nM gp61) and co-cultured with OxPAPC- and DPPC-treated splenic dendritic cells for 4 days. One-way ANOVA adjusted by Dunnett’s multiple
comparisons test. Bars represent mean  SD.
Data information: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
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maximum at 24 h of oxidation and remained constant at this level
during further oxidation for at least 5 days (Fig 1D). This observa-
tion suggested that generation of the anti-inflammatory OxPL
species required a certain degree of oxidation to occur. Still, once
formed, the bioactive OxPL species appeared to be relatively stable,
at least under the conditions used for PAPC oxidation in vitro.
15
10
5
0
IL
-6
 m
R
N
A
(r
el
at
iv
e 
to
 G
6p
dx
)B
G
0
1
2
3
0
4
8
12
16
20
C
A
E
F
0 μg/ml 25 μg/ml 50 μg/ml
100
101
102
103
104
100 101 102 103 104
IL-4
IF
N
-γ
0
50
100
150
0
100
200
300
0
50
100
150
200
250
0
10
20
30
0
2
4
6
8
IL
-1
2 
(n
g/
m
l)
0
20
40
60
80
100
0
20
40
60
80
100
15
0
5
10
20
0.0
0.5
1.0
1.5
2.0
2.5
0
20
40
60
IL
-6
 (n
g/
m
l)
IL
-1
2 
(n
g/
m
l)
IL
-6
 (n
g/
m
l)
nil
Fe
SO
4
Cu
SO
4 Air ni
l
Fe
SO
4
Cu
SO
4 Air
0
2
4
6
8
10
IL
-1
2 
(n
g/
m
l)
10
20
30
IL
-6
 (n
g/
m
l)
0
Ox
PA
PC
DM
SO
DP
PC
Ox
PA
PC
DM
SO
DP
PC
PAPC oxidation
Ox
PA
PC
DP
PC
15
10
5
0
Ox
PA
PC
DP
PC
IL
-1
2 
(%
)
Time of oxidation (h)
BMDMBMDC
0 8 16 24 72 120 Ctrl
(DPPC)
100
75
50
25
0
D
LPS R837 CpGPoly I:CLTA
LTA Poly I:C LPS R837 CpG
73.7 4.05
1.56
53.8 9
8.61
46.0 9.34
12.8
H
IF
N
-γ
 (n
g/
m
l)
80
60
40
20
0
8 16 32 64
Lipid (μM)
IF
N
- γ
-p
os
. (
%
) 100
80
60
40
20
0
30
40
20
10
0IL
-4
-p
os
. (
%
)
OxPAPC
DPPC
OxPAPC
DPPC
0 μg/ml
20 μg/ml
40 μg/ml
+ OxPAPC
0 μg/ml
20 μg/ml
40 μg/ml
+ OxPAPC
I
IL
-1
2 
m
R
N
A
(r
el
at
iv
e 
to
 G
6p
dx
)
* ***
* ***
**
**
* *** * ***
* ***
* ***
**
*
* **
ns
*
** * ***
* ***
* *** * ***
*
*
**
* ***
* ***
* ***
***
***
* ***
*
*
* **** ***
* ***
**
ns
ns
nsns
* ***
* ***
Figure 1.
ª 2015 The Authors EMBO Molecular Medicine Vol 7 | No 5 | 2015
Peter Bretscher et al Anti-inflammatory oxidized phospholipids EMBO Molecular Medicine
595
Published online: March 13, 2015 
The ability of OxPL to interfere with innate inflammation was
not limited to cytokine responses induced via TLR 7 (Fig 1A), since
OxPAPC also strongly suppressed the IL-6 and IL-12 secretion elic-
ited by microbial agonists of the TLRs 2, 3, 4, and 9 (Fig 1E and F).
A contribution of toxicity to these effects could be ruled out by
performing live staining and by verifying cellular metabolic activity
at the end of experiments (Supplementary Figs S1 and S2). More-
over, the fact that OxPAPC-mediated suppression similarly affected
the inflammatory response to several TLR ligands also rendered the
inactivation of a particular TLR ligand by OxPAPC (Bochkov et al,
2002; Blu¨ml et al, 2005), an unlikely explanation for the strong
effects observed in our experiments. Thus, the OxPL species formed
during the oxidative modification of PAPC potently inhibited the
innate inflammatory response of myeloid cells.
Dendritic cell (DC)-produced IL-12 is critical for directing the
differentiation of naı¨ve CD4+ T cells toward the T helper (Th) 1 cell
subset and thus essentially contributes to the shaping of adaptive
immune responses. We therefore next assessed whether the OxPL-
inhibited IL-12 production would impact the ability of DCs to license
Th1 polarization of naive T cells using an in vitro co-culture system
in which naı¨ve T-cell receptor transgenic CD4+ T cells are activated
by splenic DCs in the presence of their cognate peptide. Indeed,
prior exposure of DCs to OxPAPC inhibited their subsequent ability
to drive the generation of interferon-gamma (IFN-c)-producing Th1
T cells and instead promoted the generation of IL-4-producing Th2
T cells, whereas DPPC treatment showed no comparable effect
(Fig 1G and H). OxPAPC treatment not only reduced the frequency
of T cells producing IFN-c, but also diminished the absolute amount
of T-cell-secreted IFN-c protein (Fig 1I). Altogether, these findings
demonstrated a strong anti-inflammatory bioactivity of OxPAPC and
suggested that OxPL may influence both innate and adaptive
immune responses in vivo.
In vitro generated OxPAPC preparations represent complex
mixtures of OxPL species with distinct bioactivities
Both pro- and anti-inflammatory activities of OxPAPC have been
reported (Berliner & Watson, 2005; Bochkov et al, 2010), whereas
our results primarily revealed an anti-inflammatory effect of various
OxPAPC preparations. We reasoned that the overall bioactivity of a
given OxPAPC preparation likely results from the combined proper-
ties of its components and is thus determined by the relative
concentrations of individual pro- and/or anti-inflammatory OxPL
species present within the respective OxPAPC mixture. For example,
while OxPAPC generated using copper-catalyzed oxidation for 2 h
predominantly contained intermediate oxidation products of PAPC,
these OxPL species were almost absent after 24 h of oxidation when
the strongest bioactivity was detected (Fig 2A). Instead, OxPAPC
oxidized with copper sulfate for 24 h contained substantial amounts of
more complex oxidation products, such as 1-palmitoyl-2-(5-oxovaleroyl)-
sn-glycero-3-phosphocholine (POVPC), 1-palmitoyl-2-glutaryl-sn-
glycero-3-phosphocholine (PGPC), 1-palmitoyl-2-(5,6-epoxyisoprostane
E2)-sn-glycero-3-phosphocholine (PEIPC), and 1-palmitoyl-2-(5,6-
epoxyisoprostane A2)-sn-glycero-3-phosphocholine (PECPC) (Fig 2A).
To identify the anti-inflammatory OxPL species, we therefore
deliberately varied both the oxidation times and oxidative agents in
order to generate a panel of different OxPAPC preparations that
exhibited titrated degrees of anti-inflammatory bioactivity. We then
examined the OxPL composition of the differentially oxidized
OxPAPC preparations by mass spectrometry analysis and investi-
gated whether the overall bioactivity of these complex OxPL mixtures
correlated with the abundance of any of their OxPL components
(Fig 2B). Our results suggested previously known OxPL, such as
PGPC, POVPC, PEIPC, and 1-palmitoyl-2-(5-keto-6-octene-dioyl)-sn-
glycero-3-phosphocholine (KOdiAPC) as likely candidates, but also less
well-characterized OxPL species including PECPC, or even OxPL of yet
undetermined structure. Thus, the correlative analysis of bulk OxPL
mixtures indicated a limited number of candidate lipids as potential
anti-inflammatory OxPAPC components (Fig 2B).
An OxPL containing a fatty acid epoxycyclopentenone mediates
the anti-inflammatory bioactivity of OxPAPC
To unambiguously identify the relevant OxPL species, we next
tested the bioactivity of each of these candidate lipids in isolated
form using synthetic compounds. We focused our analysis on OxPL
that was either commercially available or synthesized by us accord-
ing to recently established routes (Egger et al, 2013). While PEIPC
showed an anti-inflammatory bioactivity similar to that of OxPAPC,
the less characterized PECPC exhibited slightly higher efficacy
(Fig 3A). In contrast, neither of the truncated OxPL associated with
cardiovascular inflammation (Watson et al, 1997; Podrez et al,
2002), for example, POVPC, PGPC, or KOdiAPC, inhibited the TLR-
induced inflammatory response in our experiments (Fig 3A). The
close structural homology of the fatty acid epoxycyclopentenone
detected at the sn2 position of PECPC to the endogenous, pro-resolving
prostaglandin 15-deoxy-D12,14-Prostaglandin J2 (15d-PGJ2)
prompted us to further explore the functional relationship between
PECPC and 15d-PGJ2. Given that 15d-PGJ2 is physiologically gener-
ated and active as the isolated prostanoid in vivo, we also examined
the corresponding fatty acid epoxycyclopentenone (EC) and fatty
acid epoxyisoprostane (EI) in our bioassays (Fig 3C and D). While
the inhibition of cytokine production provided by PECPC and PEIPC
exceeded that of 15d-PGJ2 by an order of magnitude, the prosta-
noid-like EI and EC exhibited a 40-fold and 100-fold stronger bioac-
tivity than 15d-PGJ2, respectively (Fig 1C and D). Thus, EC and EI
appeared to represent the active components of PECPC and PEIPC,
as their efficacy greatly increased when provided to cells in isolated
form, that is, not esterified to a lysophospholipid. Accordingly, also
the bioactivity of the synthetic phospholipid 1-palmitoyl-2-(15-
deoxy-D12,14-Prostaglandin J2)-sn-glycero-3-phosphocholine (15d-
PGJ2-PC), which contains 15d-PGJ2 esterified at the sn2 position,
showed much weaker effects than 15d-PGJ2 itself (Fig 3E).
Together, these findings identified PECPC and PEIPC as the OxPL
species mediating the anti-inflammatory bioactivity of bulk OxPAPC
preparations and suggested that they mimic the physiological activ-
ity of the endogenous, pro-resolving lipid mediator 15d-PGJ2. This
notion was further corroborated by the ability of EC and 15d-PGJ2
to modulate Th-cell polarization in our in vitro co-culture system
(Fig 3F). As could have been anticipated from above observations,
EC and 15d-PGJ2 as well as their respective OxPL, PECPC, and 15d-
PGJ2PC efficiently limited Th1-cell polarization, whereas POVPC,
PGPC, and KOdiAPC had no such effect (Fig 3F) consistent with the
inability to inhibit IL-12 production (Fig 3A and C). Collectively,
these data identified EC as the most potent anti-inflammatory
OxPAPC component and implicated the molecular pathways that
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are physiologically targeted by 15d-PGJ2 as potential mechanism for
this activity.
Epoxycyclopentenone lipids inhibit the inflammatory
response of myeloid cells via nuclear factor E2-related factor 2
(Nrf2) signaling
Our previous results described a potent anti-inflammatory effect of
OxPAPC and identified EC as principal mediator of this bioactivity.
In addition, the close structural and functional similarity between
EC and 15d-PGJ2 suggested both molecules induced these effects by
activating similar signaling pathways. 15d-PGJ2 has been reported
to interact with the nuclear hormone receptor peroxisome prolifera-
tor-activated receptor-gamma (PPAR-c) as well as with the oxidative
stress-responsive transcription factor Nrf2. Since both molecules
have been implicated in the transcriptional regulation of inflamma-
tion, we next examined their contribution by assessing the anti-
inflammatory activity of a series of synthetic OxPL in the respective
gene-deficient BMDC (Fig 4A). Whereas removal of PPAR-c did not
alter the OxPL-mediated inhibition of IL-12 production, the bioactiv-
ity of OxPAPC, EC, and 15d-PGJ2 was abrogated in the absence of
Nrf2, demonstrating that EC and related OxPL signal through Nrf2
to mediate their anti-inflammatory effects. Indeed, stimulation with
EC rapidly induced an Nrf2-dependent transcription of the proto-
typic Nrf2 targets Hmox1 and Nqo1 (Fig 4B). Similar to EC, also
15d-PGJ2 triggered the expression of the Nrf2-regulated genes Gclc
and Gsta3 in wild-type and PPAR-c-deficient cells, but not in cells
lacking Nrf2 (Fig 4C), implying that both lipids mediated their
anti-inflammatory activity via Nrf2 rather than PPAR-c. Indeed, EC
and 15d-PGJ2 inhibited the transcription of IL-6 and IL-12 genes in
TLR-stimulated wild-type and PPAR-c-deficient macrophages with
comparable efficacy, while Nrf2-deficient cells remained unaffected
by this treatment. Together, these results demonstrated that EC and
15d-PGJ2 inhibited pro-inflammatory cytokine responses through a
shared mechanism and implicated OxPL/Nrf2 signaling in the
regulation of inflammation. The anti-inflammatory effect of the
Nrf2-activating prostanoids was not limited to IL-6 and IL-12
production, as both lipids virtually abolished the expression of
several pro-inflammatory chemokines including CCL2, CCL3, CCL4,
CCL5, and CXCL10 in TLR-stimulated BMDC (Fig 4E). Notably, we
observed that compared to wild-type controls, Nrf2-deficient cells
generally exhibited enhanced TLR-induced cytokine and chemokine
responses (Supplementary Fig S3), suggesting that Nrf2 signaling
might act as a negative regulator that sets the inflammatory tone in
response to endogenously generated OxPL or related prostanoid
lipid mediators.
EC mitigates sepsis-associated inflammation in vivo
Our study so far established EC as a potent anti-inflammatory OxPL
component that signals through Nrf2 to inhibit pro-inflammatory
cytokine and chemokine responses of myeloid cells. We next sought
to test the efficacy of EC to inhibit inflammatory responses in a
model of sepsis-associated lung inflammation in vivo. For this
purpose, mice were intravenously administered with EC or the
control phospholipid DPPC 2 h before receiving an intra-peritoneal
challenge with a lethal dose of LPS in the presence of D-galactosamine
(D-Gal). While systemic LPS/D-Gal application resulted in the
massive adhesion of blood mononuclear cells to the microvascular
lung endothelium in DPPC-treated control mice, no comparable
adhesion was observed after EC pretreatment (Fig 5A), which effi-
ciently induced Nrf2 signaling in vivo (Supplementary Fig S4).
Instead, the extent of cellular adhesion observed in the lung vascu-
lature of EC-treated animals rather resembled that of naı¨ve controls
not treated with LPS (Fig 5A). This potent effect of EC was illus-
trated by a quantitative morphometric analysis confirming that EC
pretreatment significantly reduced the number of adherent cells per
defined vessel length (Fig 5B and C). Prior i.t. administration of EC
also efficiently interfered with leukocyte migration into the lung
upon i.p. LPS challenge. In particular, EC-treated animals exhibited
significantly smaller total infiltrates and reduced absolute neutrophil
numbers in their lungs (Fig 5D and E) as compared to DPPC-treated
controls. Complementing our in vitro findings, EC also strongly
decreased the LPS-induced secretion of the pro-inflammatory cyto-
kines IL-6 (Fig 5F) and IL-12 (Fig 5G) in vivo. Thus, EC efficiently
inhibited acute inflammatory responses in vivo and protected mice
from sepsis-associated vascular and pulmonary inflammation.
Structure–function studies identify critical molecular
determinants of the anti-inflammatory bioactivity
These promising in vivo observations encouraged us to further
investigate the structure–activity relationship of EC in order to eluci-
date key structural determinants mediating its potent bioactivity.
▸Figure 3. An OxPL containing a fatty acid epoxycyclopentenone mediates the anti-inflammatory bioactivity of OxPAPC.A Selected candidate lipids were tested for their inhibitory activity on R837-induced (5 lg/ml; 18 h) cytokine secretion in BMDCs. Concentrations of indicated lipids:
PECPC (10 lM), PEIPC (10 lM), OxPAPC (40 lg/ml), DPPC (40 lg/ml), POVPC (40 lM), PGPC (40 lM), and KOdiAPC (40 lM). Representative data (mean  SD of
triplicate determinations) from one of three independent experiments are shown. ****P < 0.0001; ns, not significant; as determined by one-way ANOVA adjusted by
Sidak’s multiple comparisons test.
B Structures of the cyclopentenone-containing arachidonic acid-derived lipids EC and 15d-PGJ2.
C Dose–response curves of IL-12 secretion in BMDCs pulsed for 60 min with the indicated lipids, followed by stimulation with R837 (5 lg/ml) for 18 h. Toxic
concentrations of lipids were excluded from analysis. Mean ± SEM of triplicate determinations are shown.
D EC50 values of anti-inflammatory lipid products normalized to the capacity of 15d-PGJ2 to suppress IL-12 production in BMDCs (left panel) and their respective
bioactivities (right panel) depicted as the fold increase relative to 15d-PGJ2. Mean ± SEM of triplicate determinations are shown.
E IL-12 production of BMDC stimulated via TLR 4 (LPS; 100 ng/ml), TLR 9 (CpG; 100 nM), and TLR 7 (R837; 5 lg/ml) after pretreatment with the indicated free and
esterified versions of EC and 15d-PGJ2. Lipids were used at 1 lM (EC), 10 lM (PECPC), or 20 lM (15d-PGJ2 and 15d-PGJ2PC). Data (mean  SEM) are
representative of 3 independent experiments. **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001; determined by one-way ANOVA adjusted by Dunnett’s multiple
comparisons test.
F Analysis of the capacity of various OxPL-derived species to license splenic dendritic cells to polarize naïve CD4 T cells toward the Th2 subset. Concentrations of
indicated lipids: EC (1 lM), PECPC (10 lM), 15d-PGJ2 (20 lM), OxPAPC (40 lg/ml), DPPC (40 lg/ml), POVPC (40 lM), PGPC (40 lM), KOdiAPC (40 lM).
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We hypothesized a potential involvement of the epoxide group as
well as the endocyclic and exocyclic enones and therefore evaluated
the bioactivity of synthetic EC variants that selectively lacked these
electrophilic sites (Fig 6A and B). Our results revealed the cyclopen-
tenone double bond as main driver of the overall bioactivity, since
its removal in variant ‘MonoRed A’ completely abolished the anti-
inflammatory property of EC. This notion was further supported by
the fact that introduction of another electrophilic group, an epoxide,
at this position into ‘MonoRed A’, which led to the variant ‘Bisepox-
ide’, restored its bioactivity. In addition, also the epoxide group and
the extra-cyclic double bond in a,b position to the carbonyl group
appeared to partially contribute to the overall bioactivity, as was
illustrated by the reduced efficacy of the respective variants ‘No
Epoxide’ and ‘MonoRed B’. However, additional removal of the
double bond lacking in ‘MonoRed B’ from ‘MonoRed A’ did not
further reduce the bioactivity of resulting variant ‘BisRed’, thus
confirming the critical importance of the endocyclic enone for the
overall bioactivity of the molecule. Moreover, the ability to trigger
Nrf2 signaling and downstream anti-inflammatory effects appeared
to be restricted to cyclopentenone-containing OxPL. For example,
other prominent lipid mediators involved in the regulation of
inflammation that lack a cyclopentenone moiety, such as the
arachidonic acid-derived prostacyclin and lipoxin B4, or the omega-3
fatty acid-derived resolvin D2, neither affected the cytokine
production nor triggered Nrf2 signaling in myeloid cells in our
bioassay (Supplementary Figs S5 and S6). Taken together, these
findings defined molecular determinants of the anti-inflammatory
bioactivity of EC and provided a rationale to design customized EC
variants as anti-inflammatory compounds with improved therapeu-
tic potential.
Cyclo-EC, an EC variant with superior anti-inflammatory
bioactivity in vitro and in vivo
Considering the structural and functional similarity of EC and 15d-
PGJ2, we also tested a series of chimeric molecules that combined
features of EC and 15d-PGJ2, the synthesis of which is described in
detail elsewhere (Egger et al, 2014). In this process, we developed
the EC variant cyclo-EC (cEC), which hypothetically could be
generated by an intra-molecular nucleophilic attack of the
carboxylate-anion on one of the epoxide carbons, thus forming a
6-membered lactone ring (Fig 7A) (Egger et al, 2014). Compared to
EC, cEC exhibited superior anti-inflammatory capacity, as assessed by
inhibition of IL-6 and IL-12 production (Fig 7B), but also by the
transcriptional regulation of IL-12, IL-6, IL-23, and TNFa (Supple-
mentary Fig S7). The strong induction of several Nrf2 target genes
including Hmox1 and Nqo1 indicated that like EC, also cEC
triggered Nrf2 signaling to mediate these effects (Fig 7C and
Supplementary Fig S7). Moreover, cEC showed the most potent
inhibition of IL-12 secretion among all fatty acid cyclopentenone
OxPL tested (Fig 7D and E). Expectedly, cEC also reduced the
expression of pro-inflammatory chemokines (Fig 7F) and decreased
the infiltration of neutrophils into the lungs of LPS-challenged
animals (Fig 7G). The improved efficacy of cEC was further demon-
strated by its superior capacity to modulate the DC-licensed T-cell
differentiation in vitro (Fig 7H). In particular, we observed that cEC
still strongly biased the polarization of naı¨ve T cells at concentra-
tions at which EC only exhibited weak residual activity and no such
effects could be detected for 15d-PGJ2 and PECPC. These data not
only established cEC as a promising epoxycyclopentenone-derived
compound to be further evaluated in the treatment of inflammatory
disorders, but also recommended the class of epoxycyclopentenone-
containing OxPL as potential basis for future anti-inflammatory
therapeutics.
Discussion
In this study, we have characterized the potent anti-inflammatory
activity of OxPAPC in vitro and in vivo and identified a distinct
molecular OxPL species that mediates these effects by signaling via
the oxidative stress-responsive transcription factor Nrf2. We show
that this bioactivity is based on a common structural motif shared
by anti-inflammatory OxPL and endogenous, pro-resolving lipid
mediators, and generated a synthetic OxPL variant with increased
anti-inflammatory potency.
Our understanding of the physiological significance of OxPL for
biological processes has so far been greatly hampered by the experi-
mental difficulties to monitor or even control the complexity and
composition of experimentally produced OxPL mixtures. As a result,
there is considerable discrepancy with regard to the reported biolog-
ical effects of OxPL, as both pro-inflammatory and anti-inflammatory
activities have been demonstrated. For example, the OxPL
present in minimally oxidized LDL promote monocyte adhesion to
the vascular endothelium in atherosclerosis (Watson et al, 1997) and
induce the secretion of pro-inflammatory cytokines in endothelial
cells (Subbanagounder et al, 2002). Furthermore, a direct recogni-
tion of OxPAPC by TLR4 or TLR2 has been shown to trigger severe
inflammation in vivo (Imai et al, 2008; Kadl et al, 2011). Contrasting
these observations, OxPAPC appears to inhibit the maturation and
cytokine production of antigen-presenting cells in vitro (Blu¨ml et al,
2005), and in vivo correlates of such activity have been reported
for chronic inflammatory conditions, such as leprosy (Cruz et al,
2008) or dyslipidemia (Shamshiev et al, 2007), in which an
increased generation of OxPL negatively influences disease
outcomes. Still, the inhibitory effects of OxPAPC may also be bene-
ficial for host survival by attenuating exacerbated immune activa-
tion, for example, during bacterial sepsis (Bochkov et al, 2002).
These conflicting findings clearly emphasize the importance of
studying defined molecular OxPL species instead of bulk OxPAPC
mixtures in order to elucidate their biological properties. We there-
fore chose a systematic approach to characterize the anti-inflammatory
activity of OxPAPC. Starting from complex mixtures of in vitro
generated OxPAPC preparations, we correlated the abundance of
individual OxPL species to the overall bioactivity of the mixture and
evaluated potential candidate lipids using synthetic compounds. In
this process, we identified EC as the OxPL species that attenuates
inflammatory responses through Nrf2 signaling. Its functional and
structural homology to 15d-PGJ2 as well as the altered activity of
variant lipids lacking specific electrophilic sites strongly suggested
that the biological activities of OxPL are directly related to their
chemical structure, for instance to the presence of the cyclopente-
none motif in case of anti-inflammatory OxPL. This notion is
supported by several studies reporting very specific bioactivities
of defined OxPL, which are not shared by structurally unrelated
OxPL. For example, the truncated OxPL POVPC and PGPC induce
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Figure 4. Epoxycyclopentenone lipids inhibit the inflammatory response of myeloid cells via Nrf2 signaling.
A IL-12 production of BMDC from wild-type, Nrf2/, Pparg/, and Pparg litter mate control mice normalized to medium control (open bars). Cells were treated
with the indicated lipids (filled bars) for 60 min prior TLR 7 ligation with R837 (5 lg/ml) for 18 h. Lipids were used at starting concentrations of 40 lM (POVPC,
PGPC, and KOdiAPC), 40 lg/ml (OxPAPC), 20 lM (15d-PGJ2), and 1.25 lM (EC), depicted as black bars, and 2-fold serial dilutions thereof (gray bars). Data represent
mean  SEM of triplicates from one of three independent experiments.
B Expression of Nrf2 target genes Hmox1 and Nqo1 in wild-type and Nrf2/ BMDM stimulated with EC (2 lM) for 60 min. Gene expression levels are presented
relative to that of untreated cells after normalization to G6pdx. Data (mean  SEM) are representative of two independent experiments.
C, D mRNA expression levels of the Nrf2 targets Gclc and Gsta3 (C) and of the pro-inflammatory cytokines IL-6 and IL-12 (D) in wild-type, PPAR-c-deficient, and Nrf2-
deficient BMDM after treatment with EC or 15d-PGJ2 for 60 min followed by LPS treatment for 3 h. Expression levels are normalized to G6pdx. Data represent
mean  SEM of triplicate cultures from one of two independent experiments.
E mRNA expression of the indicated chemokines as determined by qPCR. Wild-type BMDCs were treated with EC (1 lM) or 15d-PGJ2 (20 lM) for 60 min followed by
R837 stimulation (5 lg/ml) for 3 h. Expression levels are shown normalized to G6pdx. Data (mean  SEM, n = 2) are representative of three independent
experiments.
Data information: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant; as determined by one-way ANOVA adjusted by Dunnett’s multiple comparisons
test.
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monocyte/endothelial cell interactions (Watson et al, 1997), but do
not influence DC maturation (Cruz et al, 2008). Conversely, PEIPC
has been reported to elicit IL-8 and MCP-1 secretion from endo-
thelial cells by activating the EP2 receptor (Li et al, 2006), but also
appears to negatively regulate CD1b expression and DC maturation
in human leprosy (Cruz et al, 2008). In addition, PEIPC and PECPC
were shown to restore endothelial barrier function in vitro (Birukov
et al, 2004). Furthermore, KOdiAPC and structurally similar OxPL
have been identified as a family of highly specific agonists for the
scavenger receptor CD36 (Podrez et al, 2002) that triggers OxLDL
uptake but also contributes to CD36-/TLR2-dependent apoptosis
in macrophages (Seimon et al, 2010). Thus, diverse biological
activities can be attributed to structurally distinct OxPL species, and
several cellular receptors mediating such specific OxPL recognition
have already been identified (Podrez et al, 2002; Li et al, 2006;
Seimon et al, 2010). Our present study establishes Nrf2 signaling as
an additional OxPL-sensing pathway that imparts the anti-inflammatory
effects of a defined OxPL species. In particular, we found that the
Nrf2-dependent inhibition of pro-inflammatory responses of myeloid
cells was limited to OxPL containing an epoxycyclopentenone, but
not shared by truncated OxPL such as POVPC, PGPC, or KOdiAPC.
Furthermore, the observation that Nrf2-deficient DCs exhibited
enhanced pro-inflammatory responses upon TLR stimulation
implied an essential regulatory function of Nrf2 during inflamma-
tory processes, presumably in response to endogenously formed
OxPL or related prostanoids. This is in line with reports showing
enhanced inflammatory responses and increased mortality of Nrf2-
deficient mice during septic shock (Thimmulappa, 2006). Likewise,
endogenous Nrf2 ligands, such as 15d-PGJ2, are generated during
experimentally induced acute lung injury and have been shown to
inhibit inflammation via Nrf2 (Itoh et al, 2003; Mochizuki et al,
2005). Importantly, relevant amounts of structurally related OxPL
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Figure 5. EC mitigates sepsis-associated inflammation in vivo.
A C57BL/6 mice were treated (i.v.) with 500 lg EC or DPPC control 2 h prior to i.p injection of 150 ng/g LPS together with 800 lg/g D-galactosamine. 4 h after LPS
application, lungs were perfused with PBS and embedded in paraffin. Tissue sections were hematoxylin-stained to visualize adherent cells. Bars represent 100 µm.
B, C Leukocyte adhesion to lung microvascular endothelium as determined by morphometric image analysis of lung tissue sections is presented for individual
vessels in (B) and as averages of single mice in (C). Pooled data of two independent experiments are shown (n = 10 for EC, n = 14 for DPPC). Unpaired
two-tailed t-test.
D, E C57BL/6 mice were treated with EC or DPPC by intra-tracheal instillation at 18 h (50 lg) and 1.5 h (100 lg) prior to i.p. injection of 150 ng/g LPS and 800 lg/g
D-galactosamine. Bar graphs represent absolute numbers of total infiltrating cells and of neutrophils (D). Unpaired two-tailed t-test. Data represent mean  SEM
from one of two independent experiments with at least 6 mice per group. (E) Dot plots depict exemplary gating of lung neutrophils on pregated CD45+ CD11c
SiglecF BAL cells of EC-/LPS-treated and DPPC-/LPS-treated mice.
F, G The concentrations of IL-6 (F) and IL-12 (G) in the BAL of mice treated as in (D) were quantified by ELISA. Data (mean  SEM) are representative of two
independent experiments with 3 mice per group. ****P < 0.0001; unpaired two-tailed t-test.
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have been detected under chronic inflammatory conditions in situ
(Bochkov et al, 2010) and were demonstrated to regulate anti-
oxidant gene expression via Nrf2 signaling in vivo (Jyrkka¨nen et al,
2008).
In summary, we have identified from a complex mixture of
OxPL a distinct OxPL species that efficiently suppresses the inflam-
matory responses of myeloid cells in vitro and in vivo. Our results
provide insight to the essential structural characteristics and signal-
ing of anti-inflammatory OxPL and demonstrate that both are
shared with endogenous, pro-resolving lipid mediators. In addition,
our structure–function studies facilitated the generation of an
EC-derived variant with greatly enhanced bioactivity. Together,
these findings not only highlight the potential of OxPL/Nrf2 signal-
ing for the treatment of inflammatory disorders, but should also
promote the development of novel anti-inflammatory compounds
and of improved research tools to investigate the biology of OxPL
in the future.
Materials and Methods
Mice, cells and reagents
Nrf2/ mice (Nfe2l2tm1Mym) (Itoh et al, 1997), backcrossed to
C57BL/6 for more than eight generations, were obtained from the
RIKEN BioResource Center, Japan. SMARTA mice (Tg
(TcrLCMV)Aox) (Oxenius et al, 1998) were on a full C57BL/6 back-
ground. Ppargfl/flCD11c-Cre mice were bred locally (using
Ppargtm1.2Mtz and Tg(Itgax-cre)1-1Reiz) ( Imai et al, 2004; Caton et al,
2007). The respective littermates were used as WT controls. Mice
were age-/sex-matched and were taken into experiments when
6–12 weeks old. Randomization was not used to allocate animals to
experimental groups. The group sizes for in vivo experiments were
chosen based on prior experience and published literature in order
to achieve the adequate statistical power. All animal experiments
were performed according to institutional guidelines and Swiss
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B Quantification of IL-6 and IL-12 secretion by BMDC treated with 250 nM cEC or EC for 60 min before stimulation with R837 (5 lg/ml; 18 h). Bars represent
mean  SEM from one of three independent experiments. **P < 0.01; ***P < 0.001; one-way ANOVA adjusted by Dunnett’s multiple comparisons test.
C mRNA expression of the Nrf2 targets Hmox1 and Nqo1 normalized to G6pdx expression. BMDCs were treated for 60 min with 500 nM cEC or DPPC followed by R837
stimulation (5 lg/ml) for 3 h. Data (mean  SD) are representative of three independent experiments. *P < 0.05; **P < 0.01; unpaired two-tailed t-test.
D DEC50 values of the indicated lipids and OxPL shown relative to that of EC as determined in (E).
E Dose–response curves showing the modulation of R837-induced (5 lg/ml; 18 h) IL-12 secretion in BMDCs by prior treatment with the indicated OxPL derivatives for 1 h.
F mRNA quantification of the indicated chemokines relative to G6pdx expression. BMDC were pretreated for 60 min with 500 nM cEC or the variant BisRed prior to
R837 stimulation (5 lg/ml) for 3 h. Data (mean  SD) are representative of three independent experiments. *P < 0.05; **P < 0.01; unpaired two-tailed t-test.
G Quantification and characterization of cellular infiltrates in BAL. Groups of six C57BL/6 mice were pretreated i.t. with 50 lg cEC, EC, or BisRed 24 and 2 h before
challenge with 150 ng/g LPS in the presence of 800 lg/g D-galactosamine. BAL was harvested 4 h after LPS injection, and inflammatory cells were characterized by
FACS analysis. **P < 0.01; ****P < 0.0001; one-way ANOVA with Sidak’s multiple comparisons test.
H Comparison of the capacity of cEC, EC, and PECPC (1 lM) to license splenic dendritic cells to polarize naïve CD4 T cells into IFN-c-producing (Th1) and IL-4-
producing (Th2) effector cells. Data (mean  SD) are representative of two independent experiments. One-way ANOVA adjusted by Dunnett’s multiple comparisons
test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
EMBO Molecular Medicine Vol 7 | No 5 | 2015 ª 2015 The Authors
EMBO Molecular Medicine Anti-inflammatory oxidized phospholipids Peter Bretscher et al
604
Published online: March 13, 2015 
federal regulations and were approved by the veterinary office of
the Kanton of Zurich (permissions no. 167/2011 and 109/2012).
Bone marrow cells from tibiae and femurs were isolated and differ-
entiated in vitro into BMDC in the presence of 2 ng/ml recombinant
mouse GM-CSF (BioLegend, 576308) in RPMI-1640 medium (supple-
mented with L-glutamine, HEPES, penicillin/streptomycin, and 10%
FCS). Bone marrow-derived macrophages (BMDM) were differenti-
ated from freshly isolated bone marrow cells in fully supplemented
RPMI-1640 together with 10% L929-conditioned medium. Both cell
types were harvested at day 7 and seeded at 105 cells/well into
96-well round-bottom and flat-bottom plates, respectively. Primary
splenic dendritic cells were obtained by 30-min collagenase IV diges-
tion at 37°C followed by MACS sorting with anti-CD11c MicroBeads
according to the manufacturer’s instructions. Thioglycollate-elicited
macrophages were harvested by peritoneal lavage 4 days after i.p.
injection of 1 ml 3.8% thioglycollate broth. Cells were plated and
adherent cells were used for in vitro bio-assays. SMARTA transgenic
CD4+ T cells were obtained by processing whole spleens through
70-lm nylon cell strainers followed by separation with anti-CD4
MicroBeads.
Lipids
PAPC (850459C) and DPPC (850355) were purchased from Avanti
Polar lipids and stored in chloroform at 80°C. POVPC (10031),
KOdiAPC (62945), and PGPC (10044) were all purchased from
Cayman Chemicals. Lipids were stored at 10 mg/ml in EtOH at
20°C. The lipids EC, PECPC, EI, PEIPC, 15d-PGJ2, and 15d-PGJ2PC
were synthesized as described (Egger et al, 2013, 2014). All lipids
were stored at 80°C under nitrogen atmosphere. For experimental
purposes, lipids were dissolved in DMSO to 20–50 mM in glass
flasks (Carl Roth GmbH + Co) and then further diluted in pure
RPMI-1640 medium before addition to cell suspensions. PAPC were
oxidized by air exposure, with 5–10 lM iron(II)sulfate (Sigma,
F8633-250G), or with 5–10 lM CuSO4 (Merck, 1.02790.0250) as
oxidizing agents for various time intervals. Metal-catalyzed oxida-
tion was performed in sterile PBS at 37°C in glass flasks using a
rotary wheel set at 20 rpm/min.
Mass spectrometric analysis
Data acquisition of oxidized PAPC species was performed by a
Fourier transform ion cyclotron resonance mass spectrometer
(FT-ICR-MS) (linear trap quadrupole-Fourier transform, LTQ-FT;
Thermo Scientific) coupled to an UHPLC (Accela; Thermo Scien-
tific) as described previously (Fauland et al, 2011). Briefly,
chromatography was performed on C-18 reversed-phase HPLC
and full-scan mass spectra were acquired at a resolution of
200,000 and < 2 ppm mass accuracy with external calibration.
From the FT-ICR-MS preview scan, the five most abundant m/z
values were picked in data-dependent acquisition (DDA) mode,
fragmented in the linear ion trap analyzer, and ejected at nomi-
nal mass resolution. Analysis of high-resolution full-scan data of
molecular ions was carried out by Lipid Data Analyzer (Hartler
et al, 2011), while low-resolution MS/MS data were inspected
manually for confirmation of molecular identity as described in
more detail in the Supplementary Information (Supplementary
Fig S8 and Supplementary Method).
In vitro cytokine secretion assay
Unless otherwise stated, the experimental procedure for in vitro
stimulation of lipid pulsed cells was performed as follows. Cells
were counted and plated in 96-well plates at a density of
105 cells/well. Macrophages were incubated for 2 h to allow for
adherence, whereas dendritic cells were left to equilibrate at 37°C,
5% CO2 for 1 h. Subsequently, both cell types were pulsed for
60 min by addition of indicated concentrations of the various
lipids dissolved in serum-free RPMI-1640 medium, as solubiliza-
tion with BSA or incorporation into liposomes appeared not to
enhance the observed bioactivity (Supplementary Fig S9). Cells
were then washed twice with RPMI-1640 containing 2% FCS and
stimulated with various TLR ligands for 18–20 h. Supernatants
were removed, diluted if required, and subjected to ELISA for
cytokine quantification.
Lung inflammation models
C57BL/6 mice (Charles River) were injected with 50–500 lg EC/
mouse 2 h prior to i.p. injection of ultra-pure LPS 0111:B4 (150 lg/kg;
InvitroGen) and D-galactosamine (800 mg/kg; Carbosynth Limited)
dissolved in PBS. After 4 h, mice were euthanized by injection of
pentobarbital. Mice were perfused with 10 ml PBS to avoid contami-
nation of lungs with blood leukocytes. Broncho-alveolar lavage
(BAL) was performed by tracheal catheterization and repeated infu-
sion and removal of 500 ll PBS. Lungs were paraffin-embedded for
histological analysis or digested with 1 mg/ml collagenase IV (Bio-
concept) in unsupplemented IMDM (1×) + GlutaMAX (Gibco Life
Technologies). Digested lungs were processed through 70-lm nylon
cell strainers. For flow cytometry, cells were counted and stained
with antibodies against CD11b (BioLegend, 101228, 1:1,000), F4/80
(BioLegend, 123116 and 123120, 1:300), CD115 (eBioscience, 12-
1152-81, 1:300), CD11c (eBioscience, 17-0114-82, 1:2,000), CD45
(BioLegend, 103114, 1:4,000), Siglec F (BD Bioscience, 562881,
1:300), Ly-6G (BioLegend, 127606, 1:300), Ly-6C (BioLegend,
128025, 1:2,000), GR-1 (eBioscience, 17-5931-82; 1:4,000), as well
as NOS2 (Santa Cruz, sc-650, 1:500) and with the viability dye
eFluor 780 (eBioscience, 65-0865-14, 1:4,000). Neutrophils were
identified as eFluor780CD45+CD11b+CD11cLy-6G+ cells. For
intracellular stainings, cells were first fixed with 4% PFA for 5 min
before permeabilization with 0.2% saponin. For histological analy-
sis, lung sections were removed from PFA and embedded in paraf-
fin. Leukocyte adhesion to the microvascular endothelium in lung
was determined by morphometric image analysis of hematoxylin-
stained paraffin sections. Inflammatory cell adhesion to the endo-
thelium was counted in 15–20 vessels per mouse by an investigator
blinded to the sample ID.
Gene expression analysis
Tissues were lysed in 1 ml of TRIzol Reagent (Ambion Life Technol-
ogies), and mRNA was purified according to manufacturer’s instruc-
tions. mRNA concentrations were measured with a NanoDrop
device. Contaminating DNA was digested by RNase-free DNase (Life
Technologies) and 2 lg mRNA/reaction was reverse-
transcribed by GoScriptTM Reverse Transcriptase (Promega) in the
presence of RNase inhibitor (Bioconcept). Quantitative PCR was
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performed using KAPA SYBR FAST Bio-Rad iCycler Kit (Labgene
Scientific, SA), and expression was normalized to G6pdx expression.
Comparable results were obtained using other housekeeping genes
as a reference (Supplementary Fig S10). The primer sets used in this
study are shown as Supplementary Table S1.
Co-culture experiments
CD4 T cells from SMARTA2 transgenic mice were obtained by
MACS sorting of spleen with CD4+ beads (Miltenyi Biotec, 130-049-
201). Dendritic cells were pulsed with the indicated concentrations
of lipids for 60 min, washed with medium, and co-cultured together
with CD4+ T cells in the presence of the cognate LCMV gp61-81
peptide for 4 days. Cells were then re-stimulated with PMA/ionomycin
in the presence of brefeldin A for 4 h. Polarization of T cells was
assessed by intracellular FACS staining for IL-4 (BioLegend, 504104,
1:300) and IFN-c (BioLegend, 505810, 1:4,000).
Statistical analysis
All statistical tests were performed with GraphPad Prism version
6.0d for Mac OS X. For data sets with multiple comparisons and one
control group, one-way ANOVA followed by Dunnett’s correction for
multiple comparisons was applied; for experiments with more than
one control group, Sidak’s correction was used. Equality of variances
was tested using the Brown–Forsythe test. For comparison of
means of two groups, the unpaired two-tailed Student’s t-test was
applied. The representation of the data as mean  SD or SEM,
the method of statistical evaluation as well as significance levels
are indicated in each figure legend. For enhanced clarity, the
exact P-values calculated throughout this study are provided in
Supplementary Table S2.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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